Your browser is no longer supported. Please, upgrade your browser.
KZR Kezar Life Sciences, Inc. daily Stock Chart
Kezar Life Sciences, Inc.
Index- P/E- EPS (ttm)-0.86 Insider Own22.80% Shs Outstand18.71M Perf Week14.75%
Market Cap470.18M Forward P/E- EPS next Y-2.26 Insider Trans- Shs Float15.50M Perf Month29.94%
Income-16.10M PEG- EPS next Q-0.48 Inst Own46.20% Short Float5.50% Perf Quarter55.80%
Sales- P/S- EPS this Y5.30% Inst Trans8.46% Short Ratio16.13 Perf Half Y-
Book/sh6.25 P/B4.02 EPS next Y47.30% ROA- Target Price27.00 Perf Year-
Cash/sh6.33 P/C3.97 EPS next 5Y- ROE- 52W Range14.77 - 24.89 Perf YTD41.58%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High0.96% Beta-
Dividend %- Quick Ratio33.50 Sales past 5Y- Gross Margin- 52W Low70.14% ATR1.74
Employees24 Current Ratio33.50 Sales Q/Q- Oper. Margin- RSI (14)70.49 Volatility9.85% 7.40%
OptionableNo Debt/Eq0.00 EPS Q/Q-187.80% Profit Margin- Rel Volume1.00 Prev Close23.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume52.88K Price25.13
Recom1.30 SMA2017.53% SMA5031.02% SMA20038.42% Volume52,876 Change7.49%
Jul-16-18Initiated William Blair Outperform
Jul-16-18Initiated Wells Fargo Outperform $30
Jul-16-18Initiated Jefferies Buy
Aug-29-18 08:00AM  Kezar Life Sciences to Present at 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-09-18 04:05PM  Kezar Life Sciences Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-17-18 10:00AM  Former Pappas Portfolio Company CEO Retracts Anonymous Allegations PR Newswire
Jun-29-18 02:39PM  Here's how 14 Bay Area IPOs did in the strongest first half in 4 years American City Business Journals
Jun-28-18 09:07AM  Pair of upsized Bay Area biotech IPOs head in opposite directions after raising $335M American City Business Journals
Jun-25-18 04:05PM  Kezar Life Sciences Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PR Newswire
02:37PM  The Funded: More biotech IPOs highlight Bay Area venture news this week, along with a new Jay Z VC fund American City Business Journals
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 08:05PM  Kezar Life Sciences Announces Pricing of Initial Public Offering PR Newswire
03:11PM  8 Biotech Stocks With IPOs This Week InvestorPlace
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.